About Us
About PhAMA
Industry Overview
FAQ
Contact Us
Our People
Board of Directors
Past Leaders
Secretariat
Members
Join PhAMA
Our Work
Industry Support
Strategic Partnerships
Advocacy
Committees
Capability Building
Resources
International Networks
National Networks
Initiatives
Malaysia Cancer Care Coalition (M3C)
PhAMA Self Care White Paper
Publications
Guiding Principles
Fact Book
Archives
Events
Announcements
Quick Search Article:
Category:
All
DCA letters
General News
MAB Letter
NPCB
Search
There are
26 records
that matched your search criteria
Date
Title
Category
13-Oct-2009
Caution Statement on “Increased Risk for Opportunistic Infections such as Activation of Latent Viral Infections Including BK Virus-Associated Nephropathy” required to be included in the product package insert for Immunosuppressant
Bil (44) dlm. BPFK/PPP/01/03 dated 13th October 2009
DCA letters
15-Sep-2009
Advertisement on Products for nicotine replacement therapy with MAB Approval
Bil (37) dlm KKM-55/205/001/02 Jld 5 dated 15th Sept 2009
MAB Letter
14-Sep-2009
Caution Statement on “Potential for an Increase in Risk of Suicidal Thoughts or Behaviours” required to be included in the product package insert for Antiepileptik.
Bil (43) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009
Caution Statement on “Possible Interaction between Clopidogrel and Proton Pump Inhibitors” required to be included in the product package insert for Clopidogrel
Bil (42) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009
Caution Statement on “Potential For an increase in risk of Hepatotoxicity” required to be included in the product package insert for Propylthiouracil
Bil (41) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009
Caution Statement on “Potential For an increase in risk of Hepatotoxicity” required to be included in the product package insert for Propylthiouracil
Bil (41) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters